Magnetic resonance image‐guided salvage brachytherapy after radiation in select men who initially presented with favorable‐risk prostate cancer
Open Access
- 13 August 2007
- Vol. 110 (7), 1485-1492
- https://doi.org/10.1002/cncr.22934
Abstract
BACKGROUND. The authors prospectively evaluated the late gastrointestinal (GI) and genitourinary (GU) toxicity and prostate‐specific antigen (PSA) control of magnetic resonance imaging (MRI)‐guided brachytherapy used as salvage for radiation therapy (RT) failure. METHODS. From October 2000 to October 2005, 25 men with a rising PSA level and biopsy‐proven, intraprostatic cancer at least 2 years after initial RT (external beam in 13 men and brachytherapy in 12 men) who had favorable clinical features (Gleason score ≤7, PSA < 10 ng/mL, negative pelvic and bone imaging studies), received MRI‐guided salvage brachytherapy to a minimum peripheral dose of 137 gray on a phase 1/2 protocol. Estimates of toxicity and cancer control were calculated using the Kaplan‐Meier method. RESULTS. The median follow‐up was 47 months. The 4‐year estimate of grade 3 or 4 GI or GU toxicity was 30%, and 13% of patients required a colostomy and/or urostomy to repair a fistula. An interval < 4.5 years between RT courses was associated with both outcomes with a hazard ratio of 12 (95% confidence interval [95% CI], 1.4–100; P = .02) for grade 3 or 4 toxicity and 25 (95% CI, 1.1–529; P = .04) for colostomy and/orurostomy. PSA control (nadir +2 definition) was 70% at 4 years. CONCLUSIONS. The current results indicated that MRI‐guided salvage brachytherapy in men who are selected based on presenting characteristics and postfailure PSA kinetics can achieve high PSA control rates, although complications requiring surgical intervention may occur in 10% to 15% of patients. Prospective randomized studies are needed to characterize the relative cancer control and toxicity after all forms of salvage local therapy. Cancer 2007. © 2007 American Cancer Society.Keywords
This publication has 47 references indexed in Scilit:
- Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate‐specific antigen failureCancer, 2007
- Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam IrradiationJournal of Urology, 2006
- Cancer‐specific mortality after radiation therapy with short‐course hormonal therapy or radical prostatectomy in men with localized, intermediate‐risk to high‐risk prostate cancerCancer, 2006
- Salvage Prostate Brachytherapy Following Radiotherapy FailureInternational Journal of Radiation Oncology*Biology*Physics, 2005
- Late Toxicity and Early Prostate-Specific Antigen Outcome Following Salvage Prostate Brachytherapy for Select Patients Following Primary Radiation TherapyInternational Journal of Radiation Oncology*Biology*Physics, 2005
- SALVAGE SURGERY FOR RADIORECURRENT PROSTATE CANCER: CONTEMPORARY OUTCOMESJournal of Urology, 2005
- MORBIDITY AND FUNCTIONAL OUTCOMES OF SALVAGE RADICAL PROSTATECTOMY FOR LOCALLY RECURRENT PROSTATE CANCER AFTER RADIATION THERAPYJournal of Urology, 2004
- Late genitourinary and gastrointestinal toxicity after magnetic resonance image‐guided prostate brachytherapy with or without neoadjuvant external beam radiation therapyCancer, 2003
- Salvage Radical Prostatectomy: Outcome Measured by Serum Prostate Specific Antigen LevelsJournal of Urology, 1995
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958